- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02070419
TACE With or Without Radiation Therapy in Treating Patients With Stage A-C Liver Cancer
Trans-Arterial Chemo-Embolization (TACE) vs TACE Plus Stereotactic Body Radio Therapy (SBRT) in the Treatment of Hepatocellular Carcinoma (HCC)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine in patients with stage A to C hepatocellular carcinoma, if stereotactic body radiotherapy after TACE enhanced the response rate of hepatocellular carcinoma (HCC) when compared to TACE alone at 3 months.
SECONDARY OBJECTIVES:
I. To determine in patients with stage A to C hepatocellular carcinoma, if TACE plus SBRT can achieve a downstaging rate of >= 30% at 3 and 6 months.
II. To determine the rate of grade 3 or 4 adverse events associated with SBRT for liver tumors.
III. To determine the rate of local progression after SBRT. (Based on Response Evaluation Criteria in Solid Tumors [RECIST] criteria) IV. Number of patients who achieve liver transplantation. V. Overall survival.
OUTLINE: Patients are randomized to 1 of 2 treatment arms after the first loco-regional therapy with TACE.
ARM I: Patients undergo TACE according to institutional standard with doxorubicin-eluting beads.
ARM II: Patients undergo TACE as in Arm I and 3 or 5 fractions of SBRT given at least 48 hours apart over 14 days.
After completion of study treatment, patients are followed up at 1, 3, and 6 months and then periodically thereafter.
Study Type
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- HCC is staged as Barcelona A to C
- Treatment with SBRT can occur within 6 weeks of registration
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Patient has
- Radiographic enhancing liver lesions with early wash out on triple phase CT or MRI or
- Histological confirmation of HCC as determined by the Liver Tumor Board
- Hemoglobin greater than 10.0 g/dL
- Total bilirubin less than 3.0 mg/dL
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 3 X institutional upper limit of normal
- Alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 X institutional upper limit of normal
- Total aggregate of maximal dimension of liver tumors is =< 8 cm
- Cirrhotic patients Child Pugh class A or B (score =< 7)
- Patient must be determined by the treating physician to be medically eligible for liver transplantation measured by imaging modality (magnetic resonance imaging [MRI]/computed tomography [CT] scan) three months post final treatment
- Absolute neutrophil count >= 1,500/μl
- Platelet count >= 50,000 μl (after transfusion if required)
- Life expectancy > 12 weeks
- Subjects must have the ability to understand and be willing to provide written informed consent
- Women of child-bearing potential must have a negative pregnancy test within 4 weeks to the start of the SBRT treatment
- Women must not be pregnant or nursing
- Sexually active women must agree to use accepted forms of birth control; acceptable options for birth control will be documented in the consent and discussed with the subject prior to enrollment
Exclusion Criteria:
- Patient with previous history of abdominal radiation
- Cirrhotic patients Child Pugh class B with score >= 8
- Prior invasive malignancy other than primary liver malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years
- Evidence of metastatic disease prior to registration
- Evidence of main portal vein thrombosis
- History of known cardiac ischemia or stroke within last 6 months
- Any concurrent medical or psychosocial condition that prohibits a major surgical procedure or immunosuppression that would constitute a contraindication to liver transplantation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm I (TACE)
Patients undergo (transarterial chemoembolization) TACE according to institutional standard with doxorubicin-eluting beads.
|
Undergo TACE with doxorubicin-eluting beads
Other Names:
|
Experimental: Arm II (TACE+SBRT)
Patients undergo transarterial chemoembolization (TACE) as in Arm I and 3 or 5 fractions of stereotactic radiosurgery (SBRT) given at least 48 hours apart over 14 days.
|
Undergo TACE with doxorubicin-eluting beads
Other Names:
Undergo SBRT
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage change in gross tumor volume (GTV)
Time Frame: Baseline to 3 months
|
Percentage of tumor response as defined as change in longest diameter of tumor compared to original tumor length
|
Baseline to 3 months
|
Difference in mean gross tumor volume (GTV), assessed using the RECIST method
Time Frame: Baseline to 3 months
|
Difference in mean GTV from T0M and T3M calculated by a student t-test
|
Baseline to 3 months
|
Difference in tumor grade
Time Frame: Baseline to 3 months
|
Difference in the grade of tumor (as defined by the RECIST criteria) at T0 and T3 calculated using Chi-square tests.
|
Baseline to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of downstaging
Time Frame: Up to 6 months
|
Rate of downstaging of stage A to C Hepatocellular Carcinoma using TACE plus SBRT when compared to TACE at 3 and 6 months.
|
Up to 6 months
|
Grade 3 or 4 adverse events associated with liver tumors
Time Frame: Up to 1 year
|
Number of grade 3 or 4 adverse events associated with SBRT for liver tumors, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events
|
Up to 1 year
|
Rate of local progression, based on RECIST criteria
Time Frame: Up to 6 months
|
Rate of local disease progression when progression is defined as an estimated increase of > 20% in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since the treatment started or the appearance of one or more new lesions.
|
Up to 6 months
|
Liver transplant achievement
Time Frame: Up to 6 months
|
Number of patients who achieve liver transplantation
|
Up to 6 months
|
Survival rate
Time Frame: 1 year
|
The number of days from the first day of treatment on study until death of any cause
|
1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Juan Sanabria, Case Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CASE2212
- P30CA043703 (U.S. NIH Grant/Contract)
- NCI-2014-00246 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CASE 2212 (Other Identifier: Case Comprehensive Cancer Center)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Adult Primary Liver Cancer
-
University of CincinnatiActive, not recruitingLiver Metastases | Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Resectable Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States, Singapore
-
University of WashingtonNational Cancer Institute (NCI)TerminatedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular CarcinomaUnited States
-
Case Comprehensive Cancer CenterWithdrawnAdvanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma
Clinical Trials on transarterial chemoembolization
-
Zagazig UniversityCompletedHepatocellular Carcinoma
-
Brno University HospitalMasaryk University; Masaryk Memorial Cancer InstituteCompletedHepatocellular Carcinoma | Hepatocellular Carcinoma by BCLC Stage
-
Seoul National University HospitalWithdrawnHepatocellular CarcinomaKorea, Republic of
-
Second Affiliated Hospital of Guangzhou Medical...RecruitingHepatocellular Carcinoma Non-resectableChina
-
Gang WuNot yet recruitingGastric Cancer | Embolization
-
University of MinnesotaCompletedHepatocellular Carcinoma | BilirubinemiaUnited States
-
King Faisal Specialist Hospital & Research CenterUnknownHepatocellular CarcinomaSaudi Arabia
-
Peking University Cancer Hospital & InstituteNot yet recruitingHCC | Regorafenib | Transarterial Chemoembolization | Hepatic Arterial Infusion Chemotherapy
-
Stanford UniversityTerminatedCarcinoma, Hepatocellular | Hepatobiliary Neoplasm | Liver CarcinomaUnited States
-
Guangdong Provincial People's HospitalCompletedHepatocellular Carcinoma | Circulating Tumor Cell;China